文献リスト

1) Vauthey JN. Colorectal liver metastases: treat effectively up front and consider the borderline resectable. J Clin Oncol. 2007; 25: 4524

2) Petrelli NJ. Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol. 2008; 30: 4862

3) Shimada H, Tanaka K, Endou I, et al. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg. 2009; 394: 973

4) Nasti G, Ottaiano A, Berretta M, et al. Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemother Pharmacol. 2010; 66: 209

5) Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin Oncol. 2010; 28: 2300

6) 斎藤誠哉, 別府 透, 林 尚子, 他. I. 大腸癌化学療法update 2, 大腸癌肝転移に対する肝切除への化学療法の効果. In: 武藤徹一郎, 監修. 大腸疾患NOW2010. 東京: 日本メディカルセンター; 2010. p.25-35

7) 秦正二郎, 三瀬祥宏, 長谷川潔, 他. 大腸癌肝転移に対する治療. 2. 外科的治療 a) 肝切除術式. 外科. 2010; 72: 123

8) 辛島龍一, 別府 透, 近本 亮, 他. 大腸癌肝転移に対する治療. 4. 集学的治療 b) 術前化学療法併用肝切除. 外科. 2010; 72: 148

9) 高橋慶一, 山口達郎, 松本 寛, 他. 大腸癌肝転移に対する治療. 2. 外科的治療 b) 肝切除のタイミングと適応. 外科. 2010; 72: 128

10) 冨田尚裕, 野田雅史, 松原長秀, 他. 特集 大腸癌肝転移に対する治療. 4. 集学的治療 a)肝切除後の補助化学療法. 外科. 2010; 72: 139

11) 山本順司, 初瀬一夫, 柿原 稔, 他. 特集 大腸癌肝転移に対する治療のUpdate. 大腸癌肝転移に対する治療法の変遷. 外科治療. 2010; 102: 829

12) 竹村信行, 長谷川潔, 秦正二郎, 他. 特集 大腸癌肝転移に対する治療のUpdate. 大腸癌肝転移に対する肝切除の治療成績と予後因子. 外科治療. 2010; 102: 829

13) 冨田尚裕, 野田雅史, 松原長秀, 他. 特集 大腸癌診療のトピックス. 切除不能・再発癌に対する分子標的治療と最新化学療法. 消化器外科. 2010; 33: 243

14) 大腸癌研究会, 編. 大腸癌治療ガイドライン 医師用2010年版. 東京: 金原出版; 2010

15) NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology™, Colon Cancer V.1. 2011; www.nccn.org (updated on Sep. 10. 2010)

16) Zakaria S, Donofue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems？ Ann Oncol. 2007; 246: 183

17) Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007; 246: 806

18) Kanemitsu Y, Kato T. Prognostic models for predicting death after hepatectomy in individuals with hepatic metastases from colorectal cancer. World J Surg. 2008; 32: 1097

19) Yamaguchi T, Mori T, Takahashi K, et al. A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology. 2008; 55: 173

20) Welsh FK, Tekkis PP, John TG, et al. Predictive models in colorectal liver metastases - can we personalize treatment and outcome？ Dig Surg. 2008; 25: 406

21) 大腸癌研究会, 編. 大腸癌取扱い規約第7版補訂版. 東京: 金原出版; 2009

22) Gold JS, Are C, Kornprat P, et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg. 2008; 247: 109

23) Nuzzo G, Giuliante F, Ardito F, et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery. 2008; 143: 384

24) de Haas RJ, Wicherts DA, Flores, E, et al. R1 resection by necessity for colorectal liver metastases; is it still a contraindication to surgery？ Ann Surg. 2008; 248: 626

25) Adam R, de Haas RJ, Wicherts DA, et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement？ J Clin Oncol. 2008; 26: 3672

26) Oussoultzoglou E, Romain B, Panaro F, et al. Long-term survival after liver resection for colorectal liver metastases in patients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann Oncol. 2009; 249: 879

27) Adam R, Aloia T, Wicherts DA, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007; 25: 4593

28) Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases; myth or reality？ J Clin Oncol. 2008; 26: 1635

29) Adam R, Wicherts DA, de Haas RJ, et al. Patients with initially unresectable colorectal liver metastases; is there a possibility of cure？ J Clin Oncol. 2009; 27: 1829

30) Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677

31) Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25: 1670

32) Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer; a randomized phase III study. J Clin Oncol. 2008; 26: 2013

33) Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009; 249: 420

34) Van Cutsem E, Rivera F, Berry F, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropirimidines in metastatic colorectal cancer; the BEAT study. Ann Oncol. 2009; 20: 1842

35) Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360: 1408

36) Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer. 2009; 101: 1033

37) Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: CELIM randomised phase 2 trial. Lancet Oncology. 2010; 11: 38

38) Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008; 247: 118

39) Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010; 28: 2549

40) 山浦秀和, 稲葉吉隆, 佐藤洋造, 他. 大腸癌肝転移に対する治療. 4. 集学的治療 c) 集学的治療における肝動注化学療法の位置づけ. 外科. 2010; 72: 153

41) Iguchi T, Arai Y, Inaba Y, et al. Hepatic arterial infusion chemotherapy through a port-catheter system as preoperative initial therapy an patients with advanced liver dysfunction due to synchronous and unresectable liver metastases from colorectal cancer. Cardiovasc Intervent Radiol. 2008; 31: 86

42) Kemeny NE, Huitzil Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastasis from colorectal carcinoma. J Clin Oncol. 2009; 27: 3465

43) Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet. 2008; 371: 1007

44) Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009; 20: 985

45) Gallagher DJ, Zheng J, Capanu M, et al. Response to neoadjuvant chemotherapy does not predict overall survival with synchronous colorectal hepatic metastases. Ann Surg Oncol. 2009; 16: 1844

46) Mirty E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: pooled analysis of two randomized trials. J Clin Oncol. 2008; 26: 4906

47) Kokudo N, Hasegawa K, Makuuchi M. Control arm for surgery alone is needed but difficult to obtain in randomized trials for adjuvant chemotherapy after liver resection for colorectal metastases. J Clin Oncol. 2007; 25: 1299

48) Kanemitsu Y, Kato T, Shimizu Y, et al. A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer; Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol. 2009; 39: 406

49) Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastasis from colorectal cancer. Ann Oncol. 2009; 20: 1964

50) 堀内彦之, 石川博人, 久下 亨, 他. 大腸癌肝転移に対する治療. 3. Ablationの成績と位置づけ. 外科. 2010; 72: 134

51) 山門亨一郎. 特集 大腸癌肝転移に対する治療のUpdate. ラジオ波焼灼治療の成績と肝転移治療における位置づけ. 外科治療. 2010; 102: 842

52) Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol. 2007; 14: 1161

53) Veltri A, Sacchetto P, Tosetti O, et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc Intervent Radiol. 2008; 31: 948

54) Gillam AR, Lees WR, Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases. J Vasc Interv Radiol. 2008; 17: 712

55) Park IJ, Kim HC, Yu CS, et al. Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Oncol. 2008; 15: 227

56) Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumor; an analysis of 1032 tumors. Ann Surg Oncol. 2008; 15: 2757

57) Hur H, Ko, YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009; 197: 728

58) Reuter NP, Woodall CE, Scoggins CR, et al. Radiofrequency ablation vs resection for hepatic colorectal metastasis; therapeutically equivalent？ J Gastrointest Surg. 2009; 13: 486

59) Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2009; 27: 493

60) Hendlisz A, den Eynde MV, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010; 28: 3687

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp